A. B16 tumors established s.c. in WT mice were treated i.t. with 50 μg of poly-ICLC in 50 μl PBS or PBS alone as a control. Two days post-treatment, TILeus were examined via FACS. B to D. B16 tumors established s.c. in WT mice were treated i.t. with 50 μg of poly-ICLC in 50 μl PBS or PBS when tumors reached 100 – 300 mm3. Two days later, nutlin-3a or PBS was injected i.t. twice, one day apart. B. The size of B16 tumors in various treatment groups were measured every day. (n = 10 – 20). Representative images of tumor size comparison at the end of the experiment (top, C = control, N = nutlin-3a, P = Poly-IC, P+N = poly-IC + nutlin-3a). C. Representative B16 histology analysis (H&E, top) and TUNEL staining of dying cells (bottom) in different treatment groups. Scale bars = 50 μm. D. Representative images of immunofluorescence staining of TILeu-CD11b+ myeloid cells, CD3+ and CD8+ T cells. Scale bars = 50 μm. B. ** p < 0.01, two-way ANOVA.